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Protocol
AbstrACt
Introduction Depressive disorder is common in 
children and adolescents, with important consequences 
and serious impairments in terms of personal and 
social functioning. While both pharmacological and 
psychological interventions have been shown to be 
effective, there is still uncertainty about the balance 
between these and what treatment strategy should 
be preferred in clinical practice. Therefore, we aim to 
compare and rank in a network meta-analysis (NMA) 
the commonly used psychological, pharmacological 
and combined interventions for depressive disorder in 
children and adolescents.
Methods and analysis We will update the literature 
search of two previous NMAs for the identification of 
trials of antidepressant and psychotherapy alone for 
depressive disorder in children and adolescents. For 
identification of trials of combination interventions, 
seven databases (PubMed, EMBASE, CENTRAL 
(Cochrane Central Register of Controlled Trials), Web of 
Science, PsycINFO, CINAHL, LiLACS) will be searched 
from date of inception. We will also search  ClinicalTrials. 
gov, the WHO International Clinical Trials Registry 
Platform and check relevant reports on the US Food 
and Drug Administration website for unpublished data. 
Building on our previous findings in the field, we will 
include any commonly prescribed oral antidepressants 
and any manualised or structured psychotherapies, 
as well as their combinations. Randomised controlled 
trials assessing any active intervention against active 
comparator or pill placebo/psychological controls in 
acute treatment for depressive disorder in children and 
adolescents will be included. The primary outcomes 
will be efficacy (mean change in depressive symptoms), 
and acceptability of treatment (dropout rate due to any 
cause). The secondary outcomes will be remission rate, 
tolerability of treatment (dropouts for adverse events), as 
well as suicide-related outcomes (suicidal behaviour or 
ideation). We will perform Bayesian NMAs for all relative 
outcome measures. Subgroup analyses and sensitivity 
analyses will be conducted to assess the robustness of 
the findings.
Dissemination This NMA will provide the most 
up to date and clinically useful information about 
the comparative efficacy and acceptability of 
antidepressants, psychological intervention and their 
combination in the acute treatment of children and 
adolescents with depressive disorder. This is the newest 
NMA and therefore these results are very important in 
terms of evidence-based medicine. The results will be 
disseminated through peer-reviewed publication.
Protocol registration PROSPERO CRD42015020841.
strengths and limitations of this study
 ► The network meta-analysis (NMA) can integrate 
direct evidence with indirect evidence from multiple 
treatment comparisons and multiple control 
approaches to estimate the inter-relations across 
all treatments, which can guide treatment decisions 
and guideline development.
 ► For the first time the efficacy, acceptability, 
tolerability and suicide-related outcomes of 
pharmacological and psychological interventions, 
alone or in combination for depressive disorder in 
children and adolescents will be comprehensively 
assessed in a NMA.
 ► We will employ validated local and global methods 
to evaluate consistency and we will explore 
whether treatment effects are robust in network 
subgroup analyses and sensitivity analyses. The 
quality of evidence for network estimates of the 
primary outcomes will be assessed with the GRADE 
framework, which characterises the quality of a body 
of evidence on the basis of the study limitations, 
imprecision, heterogeneity or inconsistency, 
indirectness and publication bias.
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bACkgrounD
Depressive disorder in children and adolescents is a major 
public health problem, affecting 1%–2% of children 
(6–12 years old) and 2%–5% of adolescents (13–18 years 
old), with a peak incidence around puberty.1 2 The course 
of depressive disorder in children and adolescents is 
often characterised by protracted episodes, frequent 
recurrence and comorbid psychiatric disorders.3 
Compared with adults, the identification and diagnosis 
of depressive disorder in children and adolescents may 
be more often missed by clinicians4 due to undifferen-
tiated signs and symptoms and atypical presentations. 
Thus, many such patients exhibit serious impairments 
in social functioning (eg, poor school achievement; rela-
tional problems with family members and peers),5 and 
are significantly increased risk for suicidal behaviours 
and suicidal ideation.6 For example, a report from the 
American Academy of Child and Adolescent Psychiatry 
(AACAP) suggested that depressive disorder is contrib-
uted to over 500 000 suicide attempts by children and 
adolescents a year.7
The past two decades have seen significant increases 
in the data for children and adolescents with depres-
sion and both pharmacological and psychological 
therapies have been effective. Among current psycho-
logical interventions, based on our previous findings, 
cognitive behavioural therapy (CBT) and interper-
sonal psychotherapy (IPT) seem to be the best available 
psychotherapies for depression in children and adoles-
cents.8 9 Multiple pharmacological therapies have also 
been studied for the treatment of depressive disorder 
in children and adolescents.10–12 The controversy about 
the use of antidepressants in this age group, due to the 
potentially increased risk of suicidality, has not been fully 
resolved.13 Recently, the findings of our previous studies 
showed most antidepressants do not seem to offer a clear 
benefit for children and adolescents, and fluoxetine is 
probably the best option to consider when a pharmaco-
logical treatment is indicated.10
Several clinical practice guidelines recommend that 
in children and adolescents, psychotherapy should be 
considered as the first-line intervention for the manage-
ment of depressive disorder, while pharmacological 
treatments are often reserved for more severe illness or 
when psychotherapy does not work or is not available.14 15 
Nevertheless, the evidence-base for psychotherapy to be 
more effective and safer than antidepressants in the treat-
ment of child and adolescent depressive disorder is 
not well established. A large, non-industry funded trial 
reported superior efficacy for fluoxetine compared with 
CBT in adolescents with major depression.16 Previous 
research supports the notion that psychotherapy has 
its own side effects, such as dependency on the thera-
pist, and leading to distress for the patients’ family.17 
However, unlike with antidepressants, they are rarely 
measured systematically, making the comparison of safety 
and tolerability harder.18 Moreover, data from the adult 
studies showed that combination antidepressants and 
psychotherapy is superior to either intervention alone.19 20 
Recently, a Cochrane conventional meta-analysis, on the 
basis of the very limited evidence, reported that the effec-
tiveness of psychological interventions, antidepressant 
medication and a combination of these interventions for 
treating depressive disorders in children and adolescents 
cannot be established.21
Network meta-analysis (NMA) has the advantage that 
all interventions that have been tested in randomised 
controlled trials (RCTs) can be simultaneously compared, 
without requiring direct within-study treatment versus 
treatment comparisons. Thus effects of the different 
treatments can be estimated relative to each other as well 
as to a common reference condition (eg, pill placebo or 
psychological controls).22 NMA thus overcomes some 
of the limitations of traditional meta-analysis, in which 
conclusions are largely restricted to comparisons between 
treatments that have been directly compared in RCTs.23 
In our two previous NMAs, the comparative efficacy and 
acceptability of psychotherapies and antidepressants for 
depressive disorder in children and adolescents have 
been separately investigated.8 10 The aim of the current 
protocol is to synthesise all this evidence and provide clini-
cians with a reliable treatment algorithm of the commonly 
used psychological and pharmacological interventions, 
as well as their combinations for the acute treatment of 
depressive disorder in children and adolescents.
MethoDs
Criteria for included studies
Types of studies
Any RCTs, including the first phase of cross-over trials 
as well as cluster-randomised trials, will be included. 
Quasi-randomised trials (eg, those allocating participants 
using alternate days of the week) will be excluded. For 
trials of antidepressants alone, only double-blind RCTs 
(patients and raters blinded) will be included. As it is 
difficult to use a double-blind design for patients in trials 
of psychotherapy alone or the combination of antide-
pressant and psychotherapy, we will only include trials in 
which raters were blinded or participants were assessed by 
self-rating depression scales.
Types of participants
We will include studies that enrolled participants aged 
less than 18 years of age when they are initially enrolled 
in the studies, of both sexes with a diagnosis of depres-
sive disorder, including of major depressive disorder 
(MDD), dysthymia and other specified types, based on 
standardised diagnostic criteria (eg, the Diagnostic and 
Statistical Manual of Mental Disorders or the Interna-
tional Classification of Diseases).24–29 While it is accepted 
that subclinical depression still has a significant impact on 
an individuals’ social and educational functioning, we will 
not include studies of this population. Similarly, studies 
where depressive disorder was not formally diagnosed will 
also be excluded for the same rationale that its clinical 
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heterogeneity could violate the transitivity assumption in 
NMA (ie, one can compare indirectly intervention B and 
C via intervention A).30 We will also exclude trials in which 
participants are described as having psychotic depres-
sion or treatment-resistant depression, as their treatment 
response differs from patients without treatment resis-
tance or symptoms of psychosis. Trials focusing on child 
or adolescent bipolar disorder will also be excluded, but 
not those involving patients with other comorbid psychi-
atric disorders as diagnosed according to standardised 
criteria (eg, anxiety disorder or attention deficit hyper-
activity disorder). Where a study includes both adults 
and children/adolescents and the randomisation had 
been stratified according this variable, the data will be 
included if data on the depressed youths can be sepa-
rately extracted from the manuscript or can be obtained 
from the authors. Studies conducted in both inpatient 
and outpatient settings will be included. RCTs recruiting 
participants with an overall sample size of fewer than 10 
patients will be excluded.
Types of interventions
For pharmacological interventions, we will include any 
commonly prescribed oral antidepressants (fixed or flex-
ible doses). These will include tricyclic antidepressants 
(TCAs; amitriptyline, clomipramine, nortriptyline, desip-
ramine, imipramine, etc), selective serotonin reuptake 
inhibitors (SSRIs; escitalopram, fluoxetine, paroxetine, 
sertraline, etc) and serotonin-norepinephrine reuptake 
inhibitors (SNRIs; venlafaxine, duloxetine), as well as novel 
agents mirtazapine and nefazodone. In terms of psycho-
logical interventions, we will include any manualised or 
structured psychotherapies, for example, behavioural 
therapy, CBT, cognitive therapy, family therapy, inter-
personal therapy, play therapy, problem-solving therapy, 
psychodynamic therapy and supportive therapy. Table 1 
provides the detailed description of psychotherapies. 
Also, we will include the combination of both above-men-
tioned psychological interventions and pharmacological 
interventions. For the pharmacological interventions, 
the control condition is always a pill placebo, while the 
psychological control conditions are waiting-list (WL), 
treatment as usual (TAU), psychological placebo or atten-
tion placebo or no-treatment (NT).
All RCTs comparing any active intervention (psycholog-
ical interventions, pharmacological interventions or their 
combinations) with either active comparators or control 
conditions for acute treatment of depressive disorder 
in children and adolescents will be included. The acute 
phase will be defined as from 4 to 16 week. We will exclude 
trials with treatment duration of less than 4 weeks, because 
the onset of benefit for most antidepressants often 
takes at least 4 weeks.31 If a study presents data for more 
than one time point within our predefined acute phase 
window or beyond 16 weeks, the 8 week (or the closest to 
8 week) will be taken as the time. Trials comparing the 
same antidepressant at different therapeutic doses will 
be merged in the same node in the network analysis so 
long as they are within the dose range licensed by drug 
regulatory agencies. Also, trials comparing the same type 
of psychological interventions, but at different numbers 
of therapeutic sessions, different delivery format (group, 
individual), different treatment medium (face-to-face, 
internet-based) and different treatment conditions (with 
or without family involvement) will be considered as the 
same node in the network analysis. We anticipate that any 
patient who meets all inclusion criteria, in principal, is 
equally likely to be randomised to any of the interven-
tions in the synthesis comparator set.
We have generated an ideal network plot that is a 
fully connected network with all expected interventions 
(figure 1).
Types of outcome measures
Primary outcomes
1. Efficacy (as a continuous outcome), measured by the 
overall mean change scores on depressive symptom 
scales (self-rated or assessor-rated), for example, 
Children’s Depression Rating Scale (CDRS-R)32 and 
Hamilton Depression Rating Scale (HAMD)33 from 
baseline to endpoint.
2. Acceptability of treatment, defined as the proportion 
of patients who drop out of the study by any cause 
during the delivery of the intervention.
Secondary outcomes
1. Efficacy (as dichotomous outcome), measured by the 
total number of patients who achieved the criteria 
of remission, defined as being below the threshold 
in depression rating score (eg, less than 28 for 
CDRS-R),34 while these thresholds are different across 
trials.
2. Tolerability of treatment, defined as the proportion 
of patients who discontinued treatment due to any 
adverse events during the delivery of the intervention.
3. Suicide-related outcome, estimated by the reported 
cases of definitive suicidal behaviour or suicidal 
ideation during the acute phase of treatment. The 
definition of suicide-related outcome is based on 
the Columbia Classification Algorithm of Suicide 
Assessment (C-CASA).35 For the antidepressants 
trials, the data on suicidality mainly referred to the 
Columbia reanalysis data reported in the Food and 
Drug Administration (FDA) report.36 If trials are not 
included in this report, we will attempt to extract the 
data on suicide-related outcome from the Medicines 
and Healthcare products Regulatory Agency database 
or the pharmaceutical company website. For the 
psychological trials and the combination trials, we will 
mainly extract the data on suicidality from original 
text and from related reviews.
4. Global functional improvement, estimated by 
overall change scores on global assessment of 
functioning scales, for example, Children’s Global 
Assessment Scale (CGAS)37 and Global Assessment of 
Functioning Scale (GAF),38 or quality of life scales, for 
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example, Quality of Life Enjoyment and Satisfaction 
Questionnaire (Q-LES-Q).39 When data are reported 
on more than one measure, we will first chose data 
from the CGAS, then the GAF and finally the Q-LES-Q 
and others.
Where depression symptoms are measured using more 
than one depression scale in a trial, we will extract data 
from the depressive scales on the basis of a hierarchy of 
rating scales. The hierarchy will be based on psychometric 
properties and appropriateness for use with children 
and adolescents and for consistency of use across trials 
(referred from the Zhou et al study,40 table 2). We will also 
establish a hierarchy of informants of depressive rating 
scales, with the clinician report first in the hierarchy, and 
then the child or adolescent self-report.
DAtA sourCes AnD seArCh strAtegy
For the identification of trials of antidepressant and 
psychotherapy alone for depressive disorder in children 
and adolescents, we will update the literature search of 
our two previous NMAs.8 10 Other eligible trials of the 
combinations of antidepressant and psychotherapy will 
be identified by searching PubMed, EMBASE, CENTRAL 
(Cochrane Central Register of Controlled Trials), Web 
of Science, PsycINFO, ProQuest, CINAHL, LiLACS from 
date of inception with Medical Subject Headings (MeSH) 
Table 1 Description of Psychotherapeutic interventions and control conditions
Interventions Abbreviation Description
Psychotherapeutic Intervention:
  Behavioural therapy BT BT uses some kind of behavioural training and psychoeducation. BT programmes provide 
parents and youths information about MDD and interventions; teach youths to monitor their 
mood, thoughts and behaviours; proposed pleasant activity scheduling and behavioural 
activation.
  Cognitive-behavioural 
therapy
CBT CBT is a combination of BT and CT. Additional CBT skill-building techniques are used in many 
programmes by teaching relaxation techniques to cope with environmental stressors, providing 
social skills and resolution training and teaching general problem-solving.
  Cognitive therapy CT CT uses some kind of cognitive restructuring training. CT programs ask youths to examine their 
automatic thoughts and core schemas and to assess the accuracy and affective consequences 
of their views. They aim to teach youths to engage in ‘rational’ thinking about themselves, the 
world and their possibilities for the future.
  Family therapy FT FT works with families to nurture change and development. FT tends to view change in terms 
of the systems of interaction between family members. In the case of youth with MDD, FT aims 
at helping the family to answer the child’s needs for completing age-appropriate developmental 
tasks to relieve depression.
  Interpersonal therapy IPT IPT aims at educating patients as to how their depression and the quality of interpersonal 
relationships affect one another and at addressing interpersonal problems that may be 
contributing to the depression (eg, grief, disputes, role transitions, social deficits). Compared with 
its adult version, IPT in youths is shorter, involves parents and adds a liaison role for the therapist 
between schools and families.
  Play therapy PT PT used techniques to engage participants in recreational activities to help them cope with their 
problems and fears.
  Problem-solving therapy PST PST focus on the problems participants are currently facing and on helping them find solutions to 
those problems.
  Psychodynamic therapy DYN DYN proposed patients to help understand the origin and nature of long standing problems by 
investigating both conscious and non-conscious thoughts and emotional feelings. DYN uses free 
associations and interpretation of dreams (or drawing in children), and addresses how personal 
history and experience may alter the patient/therapist transference. In youth MDD, a particular 
interest is given to psychological trauma, early parent/child relationships, narcissistic organisation 
and experiences of loss.
  Supportive therapy SUP SUP is an unstructured therapy without specific psychological techniques that it helped people 
to ventilate their experiences and emotions and offering empathy. These therapies are commonly 
described in the literature as either counselling or supportive therapy.
Control conditions:
  No treatment NT NT is a control condition in which the participants receive no active treatment during the study 
and in which they do not expect to receive such after the study is over.
  Psychological placebo PBO PBO is a control condition that was regarded as inactive by the researchers, but was to be the 
participants.
  Treatment as usual TAU TAU is not considered to be structured psychotherapy, but may have some treatment effects.
  Waitlist WL WL is a control condition in which the participants receive no active treatment during the study 
but are forewarned that they can receive one after the study period is over.
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and text words: (depress* or dysthymi* or mood disorder* 
or affective disorder*) and (adolesc* or child* or boy* or 
girl* or juvenil* or minors or paediatri* or pediatri* or 
pubescen* or school* or student* or teen* or young or 
youth*) and (‘selective serotonin reuptake inhibitor*’ or 
SSRIs or ‘serotonin norepinephrine reuptake inhibitor*’ 
or SNRIs or citalopram or fluoxetine or paroxetine or 
sertraline or escitalopram or fluvoxamine or venlafaxine 
or duloxetine ‘noradrenergic and specific serotonergic 
antidepressants’ or NaSSA or mirtazapine or TCA or 
tricyclic or amitriptyline or clomipramine or desipramine 
or imipramine or nortriptyline) and (psychotherapy* 
or behavio* or ‘family therap*’ or CBT or cognitive or 
interpersonal or IPT or ‘play therap*’ or supportive or 
problem-solving or psychodynamic). We will also search 
ClinicalTrials. gov in USA and other international trial 
registers viathe International Clinical Trials Registry 
Platform (ICTRP) in WHO. We will also check rele-
vant reports on the US FDA website and hand-search 
key journals, conference proceedings, such as, J Child 
Adolesc Psychopharmacol, J Am Acad Child Adolesc Psychi-
atry, Child Adolesc Psychiatry Ment Health, Psychopharmacol 
Bull, Arch Gen Psychiatry, Am J Psychiatry, Eur Psychiatry, 
Depress Anxiety. There will be no restrictions on language 
Table 2 Hierarchy of depression symptom severity measurement scales
Hierarchy Depression symptom severity measurement scales Abbreviation
1 Children’s Depression Rating Scale CDRS
2 Hamilton Depression Rating Scale HAMD
3 Montgomery Asberg Depression Rating Scale MADRS
4 Beck Depression Inventory BDI
5 Children’s Depression Inventory CDI
6 Schedule for Affective Disorders and Schizophrenia for School Aged Children K-SADS
7 Mood and Feeling Questionnaire MFQ
8 Reynolds Adolescent Depression Scale RADS
9 Bellevue Index of Depression  BID
10 Child Depression Scale CDS
11 Centre for Epidemiologic Studies Depression Scale CESD
12 Child Assessment Schedule CAS
13 Child Behaviour Checklist-Depression CBCL-D
Figure 1 Possible interventions eligible for the ideal network plot.
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or publication year. Additional relevant studies will be 
obtained by scanning reference lists of trials identified in 
the initial searches and relevant review papers. We will 
also inquire at the relative pharmaceutical companies 
(eg, GlaxoSmithKline, Lilly, Organon, Forest Pharma-
ceuticals, Bristol-Myers Squibb) and search their websites 
for unpublished data. All relevant experts and principal 
manufacturers will be contacted to supplement incom-
plete reports of the original papers or to provide new data 
for unpublished studies.
study selection and data extraction
Selection of trials
Titles and abstracts identified from the search strategies 
will be independently examined by two reviewers (XZ 
and YZ). If both reviewers judge that the trial does not 
meet eligibility criteria, we will exclude it. Then, we will 
obtain the full-texts of all remaining articles and deter-
mine whether to include them according to inclusion 
criteria described above. We will calculate the inter-rater 
reliability of the two raters. Any disagreements will be 
resolved by a third review author (AC or PX) or by consul-
tation with the authors of the articles. The reasons for 
exclusion of trials will be reported in the characteristics 
of excluded studies list.
Data extraction
Two independent reviewers (XZ and YZ) will extract the 
data from each included trial using standardised data 
extraction forms, including study characteristics (eg, first 
listed author, publication year, title, publication type, 
publication journal, country and sponsor), patient char-
acteristics (eg, diagnostic criteria, comorbidities, the age 
of patients, patient setting, the number of patients, the 
gender of patients and severity of depression at baseline), 
intervention details (eg, the type of intervention, the 
treatment duration, the dose of antidepressant agent, the 
length and number of sessions of psychotherapy, treat-
ment delivery and treatment medium of psychotherapy) 
and outcome measures (primary outcomes and secondary 
outcomes). We will assess and report the reliability of the 
reviewers’ data extraction on each coded variable. Any 
disagreements will be resolved by a third review author 
(AC or PX). Where necessary, the authors of the studies 
will be contacted for further information.
Risk of bias assessment
We will assess risk of bias as ‘low risk’, ‘unclear risk’ or 
‘high risk’, in accordance with the Cochrane Collabo-
ration’s Risk of bias tool as described in the Cochrane 
Hand book for Systematic Reviews of Interventions.41 The 
following items will be assessed: sequence generation, 
allocation concealment, blinding of participants and 
personnel, blinding of outcome assessors, incomplete 
outcome data, selective outcome reporting and other 
sources of bias (eg, sponsorship bias/researcher alle-
giance bias). Two independent review authors (XZ and 
YZ) will assess the risk of bias in selected studies. Degree 
of agreement between the two independent raters will be 
reported. Any disagreements will be resolved by a third 
review author (AC or PX). Where necessary, the authors 
of the studies will be contacted for further information. 
Studies will be classified as having high risk of bias if two 
or more domains were rated as high risk of bias; low if five 
or more were rated as low risk of bias and none was rated 
as high risk of bias, and all other cases will be assumed to 
pertain to moderate risk.
statistical analysis
NMA combines direct and indirect evidence for all relative 
treatment effects and provides estimates with maximum 
power.23 First, we will perform pairwise meta-analyses 
of direct evidence using the random-effects model with 
Stata V.14.0. Second, we will also perform a random-ef-
fects NMA within a Bayesian framework using Markov 
chain Monte Carlo in WinBUGS V.1.4.3. Where different 
measures are used to assess the same outcome, contin-
uous outcomes data will be pooled with standardised 
mean difference (SMD) and dichotomous outcomes 
will be analysed by calculating the OR. In the presence 
of minimally informative priors, credible intervals (CrIs) 
can be interpreted similarly to CIs.
Missing dichotomous outcome data will be managed 
according to the intention to treat (ITT) principle, and 
all the dropouts after randomisation will be considered to 
be non-responders. Missing continuous outcome data will 
be analysed using the completer data. When p values, t 
values, CIs orSEs are reported in articles, SD will be calcu-
lated from their values.42 Where SDs are missing, attempts 
will be made to obtain these data through contacting 
trial authors. When this fails, they will be borrowed from 
the other trials in the network or from other published 
reports.42
In the analysis of NMA , the pooled estimates will be 
obtained using the Markov Chains Monte Carlo method. 
Two Markov chains will be run simultaneously with 
different arbitrarily chosen initial values and non-infor-
mative priors will be used for the parameters. To ensure 
convergence, trace plots and the Brooks-Gelman-Rubin 
statistic will be assessed.43 We will also estimate the 
ranking probabilities for all treatments of being at each 
possible rank for each intervention. Then, we will obtain 
a treatment hierarchy using the surface under the cumu-
lative ranking curve (SUCRA) and mean ranks. SUCRA 
can also be interpreted as the percentage of efficacy/
safety of a treatment that would be ranked first without 
uncertainty.44
Measures for transitivity assumption
We will assess whether the included interventions are 
similar when they are evaluated in RCTs with different 
designs and whether the distributions of clinical and meth-
odological variables that can act as effect modifiers across 
treatment comparison are balanced across comparisons. 
The clinical features, which have been demonstrated 
to date to moderate efficacy of antidepressants and 
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psychotherapy in children and adolescents include bipo-
larity,45 psychotic features,46 subthreshold depression.47 
We have assured transitivity in our network with regard 
to these variables by limiting our samples to participants 
with non-psychotic unipolar depressive disorders. Other 
clinical or methodological variables that may influence 
our primary outcomes of treatment efficacy or accept-
ability include: age, sex, depressive severity at baseline 
and the treatment duration.
Measures for heterogeneity
In standard pairwise meta-analyses, we will estimate a 
different heterogeneity variance for each pairwise compar-
isons; in NMA we will assume a common estimate for the 
heterogeneity variance across the different comparisons. 
We will assess statistically the presence of heterogeneity 
within each pairwise comparison using the I2 statistic48 
and its 95% CI that measures the percentage of variability 
that cannot be attributed to random error. The assess-
ment for the presence of statistical heterogeneity in the 
entire network will be based on the magnitude of the 
heterogeneity variance parameter (τ2) estimated from 
the NMA models. We will also estimate a total I2 value and 
predictive intervals for heterogeneity in the network.49
Measures for inconsistency
NMA assumes that there is consistency in the network (ie, 
direct and indirect evidence are in agreement). However, 
the assumption of consistency can be violated either in the 
entire network or in certain parts (ie, loops of evidence) 
of the network.50 Therefore, consistency needs to be 
checked. We will evaluate the presence of local inconsis-
tency and global inconsistency in Stata V.14.0 and will be 
duplicated in R software.51
Measures for publication bias
We will use the contour-enhanced funnel plot and Egger’s 
test to assess risk of publication bias within each pairwise 
comparison.52 We will also use the comparison-adjusted 
funnel plots of all trials with placebo controls or inactive 
controls to investigate whether results in imprecise trials 
differ from those in more precise trials in NMA.53
Subgroup analyses and sensitivity analyses
Where possible, we will conduct the network meta-regres-
sion meta-analyses of data on primary outcomes for the: 
(1) age of participants (children vs adolescents); (2) sex 
ratio; (3) the severity of depressive symptoms at baseline; 
(4) the treatment duration; (5) severity of depressive 
symptom at baseline. If possible, we will do some extra 
subgroup analyses according to the results of heteroge-
neity and inconsistency. In the sensitivity analysis, trials 
where missing data have been imputed will be excluded, 
trials where high risk of bias rating have been assessed, 
and trials where only included patients comorbidity with 
other psychiatric disorders will be excluded. And, we will 
not only test whether the results change but also if tran-
sitivity (consistency/model fit) is affected. We will also 
examine some variables (eg, sample size of trials54), as 
continuous measure in meta-regression analyses.
GRADE quality assessment
We will also assess the quality of evidence contributing 
to primary outcomes with the GRADE framework, which 
characterises the quality of a body of evidence on the 
basis of the study limitations, imprecision, heterogeneity 
or inconsistency, indirectness and publication bias.55 The 
starting point for confidence in each network estimate 
is high, but will be downgraded according to the assess-
ments of these five aspects.
ethICs AnD DIsseMInAtIon
This NMA does not need ethical approval, as data used 
here are based on aggregated data in the public domain. 
Findings from the analysis will provide an overview and 
information on the relative efficacy and acceptability of 
antidepressant medications, psychological therapies and 
their combination for depressive disorder in children 
and adolescents. It is suggested that the findings will have 
significant implications for clinical practice and further 
research.
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